Fourth Quarter 2018 Results Conference Call

Conference Call Highlights:  Refreshed, strengthened management team Established strategic plan to become the preferred drug delivery partner for specific infusion therapies in select markets Net Revenue increased 12.4% to $17.4 million from $15.4 million Adjusted EBITDA* expanded to $2.7 million, up 73.9% from $1.6 million in 2017 This presentation contains forward-looking statements that involve risks … Continued

REPR November Investor Presentation – 11.13.18

Presentation Highlights: Net Sales increased 18.1% to $4.5 million Gross margin improved to 63.6% compared to 61.8% Net income grew to $386,553; 8.5% of net sales Don Pettigrew was appointed to President and Chief Commercial Officer on Spetmber 4th, 2018   This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited … Continued

Liolis Gateway September 2018 Presentation

Liolis Gateway Presentation Highlights: Global leader in mechanical infusion systems Flagship FREEDOM60® system enables self-administered home infusion Part of the solution to today’s healthcare challenges New senior leadership focused on growth & value creation This presentation contains forward-looking statements that involve risks and uncertainties, including but not limited to those related to the growth of … Continued

RMS Receives FDA Clearance for 510(k)

RMS Freedom Infusion System Cleared for Both Subcutaneous and Intravenous Indications CHESTER, NY / September 05, 2017 / Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) announces the FDA issued a new 510(k) clearance for the RMS “Integrated Catch-Up Freedom Syringe Driver Infusion System” effective August 31, 2017.  The Freedom System is the … Continued